garlic + lumateperone

avoid combo w/ supplemental garlic; dietary intake OK: combo may decr. lumateperone levels, efficacy; may incr. risk of hypotension, incl. orthostasis, syncope (hepatic metab. induced; additive effects)

garlic + ethinyl estradiol (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after supplemental garlic tx; dietary intake OK: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metab. induced)

garlic + norethindrone (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after supplemental garlic tx; dietary intake OK: combo may decr. norethindrone levels, contraceptive efficacy (hepatic metab. induced)

lumateperone + cariprazine

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (incl. orthostasis, syncope), other adverse effects (additive effects, duplicate tx)

posaconazole + ethinyl estradiol (contraceptive)

use alternative or monitor breakthrough fungal infection, thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects; may decr. posaconazole levels, efficacy (hepatic metab. inhibited; UGT possibly induced)

progesterone (hormone replacement) + norethindrone (contraceptive)

avoid combo: combo may incr. risk of thromboembolism, other adverse effects (additive effects, duplicate tx)

progesterone (hormone replacement) + ethinyl estradiol (contraceptive)

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

garlic + pentamidine

monitor BP w/ supplemental garlic; dietary intake OK: combo may incr. risk of severe or life-threatening hypotension (additive effects)

garlic + cariprazine

monitor BP w/ supplemental garlic; dietary intake OK: combo may incr. risk of hypotension, incl. orthostasis, syncope (additive effects)

lumateperone + pentamidine

monitor ECG, BP; risk may be lower w/ nebulized pentamidine: combo may incr. risk of QT prolongation, cardiac arrhythmias, severe or life-threatening hypotension, incl. orthostasis, syncope (additive effects)

lumateperone + posaconazole

monitor ECG; decr. lumateperone dose to 10.5 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

lumateperone + ethinyl estradiol (contraceptive)

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

pentamidine + posaconazole

monitor ECG; risk may be lower w/ nebulized pentamidine: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

pentamidine + cariprazine

monitor BP: combo may incr. risk of severe or life-threatening hypotension, incl. orthostasis, syncope (additive effects)

posaconazole + cariprazine

if starting cariprazine tx, adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 1.5 mg q3 days, then may incr. to 1.5 mg qod; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 1.5 mg q3 days; if on stable cariprazine tx and starting posaconazole, adjust cariprazine dose as follows: ALL INDICATIONS: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 1.5 mg q3 days; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qod: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metab. inhibited)

garlic + tasimelteon

caution advised w/ supplemental garlic; dietary intake OK: combo may decr. tasimelteon levels, efficacy (hepatic metab. induced)

lumateperone + tasimelteon

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

tasimelteon + cariprazine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

ethinyl estradiol (contraceptive) + cariprazine

caution advised: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metab. inhibited)